Article info

Download PDFPDF

COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al
Free

Authors

  • Milena Gianfrancesco Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Kimme L Hyrich Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Jinoos Yazdany Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Pedro M Machado MRC Centre for Neuromuscular Diseases, University College London, London, UK Rheumatology, University College London Centre for Rheumatology, London, UK PubMed articlesGoogle scholar articles
  • Philip C Robinson Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Philip C Robinson, Faculty of Medicine, The University of Queensland, Herston, QLD 4072, Australia; philip.robinson{at}uq.edu.au
View Full Text

Citation

Gianfrancesco M, Hyrich KL, Yazdany J, et al
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al

Publication history

  • Received August 4, 2020
  • Accepted August 5, 2020
  • First published August 12, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.